Agios Pharmaceuticals Inc (NAS:AGIO)
$ 60.48 1.42 (2.4%) Market Cap: 3.45 Bil Enterprise Value: 2.42 Bil PE Ratio: 5.32 PB Ratio: 2.12 GF Score: 37/100

Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 03:30PM GMT
Release Date Price: $28.99 (-1.99%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tess Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team. We are pleased to welcome Agios to kick off our Wednesday here. And speaking on behalf of the company, we have CEO, Brian Goff.

Before I turn it over to Brian, I just wanted to remind folks that there will be a Q&A after the formal presentation. There is an Ask a Question button in the portal, I'm happy to ask the question on your behalf, and then we'll also have a mike runner to take live audience questions.

So with that, Brian, over to you.

Brian M. Goff
Agios Pharmaceuticals, Inc. - CEO & Director

All right. Well, thank you, Tess, and good morning, everyone. Agios' mission is to develop transformative treatments for patients living with rare diseases, and it's truly my pleasure to speak with you today about our strategy for significant growth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot